MX2008016525A - Fused heterocyclic inhibitors of d-amino acid oxidase. - Google Patents
Fused heterocyclic inhibitors of d-amino acid oxidase.Info
- Publication number
- MX2008016525A MX2008016525A MX2008016525A MX2008016525A MX2008016525A MX 2008016525 A MX2008016525 A MX 2008016525A MX 2008016525 A MX2008016525 A MX 2008016525A MX 2008016525 A MX2008016525 A MX 2008016525A MX 2008016525 A MX2008016525 A MX 2008016525A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- amino acid
- acid oxidase
- fused heterocyclic
- heterocyclic inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. Also provided are methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure wherein Q is a member selected from O, S, CR<sup>1</sup> and N, X and Y are members independently selected from CR<sup>2</sup>, O, S, N and NR<sup>3</sup>.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80639106P | 2006-06-30 | 2006-06-30 | |
US84246506P | 2006-09-05 | 2006-09-05 | |
US91429307P | 2007-04-26 | 2007-04-26 | |
PCT/US2007/015396 WO2008005456A2 (en) | 2006-06-30 | 2007-07-02 | Fused heterocyclic inhibitors of d-amino acid oxidase |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008016525A true MX2008016525A (en) | 2009-03-09 |
Family
ID=38877507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008016525A MX2008016525A (en) | 2006-06-30 | 2007-07-02 | Fused heterocyclic inhibitors of d-amino acid oxidase. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2057162A2 (en) |
JP (1) | JP2009542683A (en) |
KR (1) | KR20090024823A (en) |
AU (1) | AU2007269646A1 (en) |
BR (1) | BRPI0713216A2 (en) |
CA (1) | CA2659060A1 (en) |
IL (1) | IL195921A0 (en) |
MX (1) | MX2008016525A (en) |
WO (1) | WO2008005456A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL380887A1 (en) | 2003-12-29 | 2007-04-02 | Sepracor Inc. | Pyrrole and pyrazole DAAO inhibitors |
EP1976513B1 (en) | 2006-01-06 | 2016-08-24 | Sunovion Pharmaceuticals Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
NZ569608A (en) | 2006-01-06 | 2011-09-30 | Sepracor Inc | Tetralone-based monoamine reuptake inhibitors |
CA2648121C (en) | 2006-03-31 | 2013-08-06 | Sepracor Inc. | Preparation of chiral amides and amines |
US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
WO2008047821A1 (en) | 2006-10-18 | 2008-04-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
AU2008259841B2 (en) | 2007-05-31 | 2015-02-05 | Sunovion Pharmaceuticals Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
AR076766A1 (en) | 2009-05-14 | 2011-07-06 | Japan Tobacco Inc | AZETIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND ITS USE IN THE TREATMENT OF AUTOIMMUNE DISEASES. |
GB201111705D0 (en) * | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
JO3115B1 (en) * | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | Pyridazinone Compounds and Their Use as DAAO Inhibitors |
GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
AU2015253099B2 (en) * | 2014-04-30 | 2019-07-18 | National Chiao Tung University | Use of known compounds as D-amino acid oxidase inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9803228D0 (en) * | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
DK1088824T3 (en) * | 1999-09-30 | 2004-04-13 | Pfizer Prod Inc | Bicyclic pyrrolylamides as glycogen phosphorylase inhibitors |
EP1391460A1 (en) * | 1999-09-30 | 2004-02-25 | Pfizer Products Inc. | Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
WO2003039540A2 (en) * | 2001-11-09 | 2003-05-15 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
US7226938B2 (en) * | 2002-09-06 | 2007-06-05 | Janssen Pharmaceutica, N.V. | Heterocyclic compounds |
PL380887A1 (en) * | 2003-12-29 | 2007-04-02 | Sepracor Inc. | Pyrrole and pyrazole DAAO inhibitors |
CN102827082B (en) * | 2004-07-01 | 2015-01-07 | 第一三共株式会社 | Thienopyrazole derivative having PDE7 inhibitory activity |
US20090069384A1 (en) * | 2005-01-19 | 2009-03-12 | Biolipox Ab | Thienopyrroles useful in the treatment of inflammation |
CA2624795A1 (en) * | 2005-10-06 | 2007-04-12 | Merck Sharp & Dohme Limited | Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as d-amino acid oxidase inhibitors |
UA95788C2 (en) * | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
-
2007
- 2007-07-02 KR KR1020097001738A patent/KR20090024823A/en not_active Application Discontinuation
- 2007-07-02 BR BRPI0713216-6A patent/BRPI0713216A2/en not_active IP Right Cessation
- 2007-07-02 EP EP07796659A patent/EP2057162A2/en not_active Withdrawn
- 2007-07-02 CA CA002659060A patent/CA2659060A1/en not_active Abandoned
- 2007-07-02 AU AU2007269646A patent/AU2007269646A1/en not_active Abandoned
- 2007-07-02 WO PCT/US2007/015396 patent/WO2008005456A2/en active Application Filing
- 2007-07-02 MX MX2008016525A patent/MX2008016525A/en not_active Application Discontinuation
- 2007-07-02 JP JP2009518342A patent/JP2009542683A/en active Pending
-
2008
- 2008-12-14 IL IL195921A patent/IL195921A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2007269646A1 (en) | 2008-01-10 |
JP2009542683A (en) | 2009-12-03 |
EP2057162A2 (en) | 2009-05-13 |
CA2659060A1 (en) | 2008-01-10 |
WO2008005456A3 (en) | 2008-07-31 |
KR20090024823A (en) | 2009-03-09 |
BRPI0713216A2 (en) | 2012-12-04 |
IL195921A0 (en) | 2009-09-01 |
WO2008005456A2 (en) | 2008-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2008016525A (en) | Fused heterocyclic inhibitors of d-amino acid oxidase. | |
TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
AP1860A (en) | Aryl fused azapolycyclic compounds. | |
EP1841426A4 (en) | Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease | |
TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
WO2007064553A3 (en) | Thiazole derivatives as cxcr3 receptor modulators | |
TW200631583A (en) | Substituted pteridines for the treatment of inflammatory diseases | |
UA83899C2 (en) | Imidazole compounds for the treatment of neurodegenerative disorders | |
SG156650A1 (en) | Thienopyrimidines useful as aurora kinase inhibitors | |
ATE385238T1 (en) | USE OF DPIV INHIBITORS AS THERAPEUTICS FOR MEDICAL NEUROLOGICAL CONDITIONS | |
WO2005065195A3 (en) | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2008045393A3 (en) | Imidazo- and triazolo-pyridine compounds and methods of use therof | |
ATE349435T1 (en) | GLUTAMINE-BASED DPIV INHIBITORS | |
MXPA05002420A (en) | Thiazole compounds for the treatment of neurodegenerative disorders. | |
WO2007070433A3 (en) | 2-arylthiazole derivatives as cxcr3 receptor modulators | |
TW200634016A (en) | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | |
WO2008030412A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2007137103A3 (en) | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme | |
TW200724543A (en) | Heterocyclic compounds and their uses as therapeutic agents | |
WO2006055434A3 (en) | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | |
SI2054418T1 (en) | Dihydrothieno pyrimidines as akt protein kinase inhibitors | |
ZA200801172B (en) | Caspase inhibitor prodrugs | |
EP2091328A4 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2003027068A3 (en) | Substituted amines for the treatment of neurological disorders | |
EP1817312A4 (en) | Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |